| MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 | 09/09 07:00 | globenewswire.com |
| MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward | 07/18 14:19 | seekingalpha.com |
| MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa | 05/16 08:00 | globenewswire.com |
| MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion | 05/12 08:37 | seekingalpha.com |
| MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update | 05/07 08:00 | globenewswire.com |
| MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions | 04/10 07:00 | globenewswire.com |
| MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions | 04/10 07:00 | businesswire.com |
| MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test | 03/11 10:41 | investors.com |
| MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day | 03/10 12:00 | globenewswire.com |
| MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 | 03/04 08:00 | globenewswire.com |